PayPay’s revenue and adjusted EBITDA both exceeded the upper ends of company guidance, with lower-than-expected loyalty-point expenses possibly the main driver; JPMorgan considers the core business solid, but says this quarter’s results are unlikely to drive a share-price recovery.
A pullback in trading volumes and an adverse foreign-exchange impact weighed on the securities business, leaving Kakao Pay’s third-quarter operating profit below market expectations. Payments and insurance grew quickly, but JPMorgan believes their scale remains insufficient to offset the cyclical fluctuations of the brokerage business.
JPMorgan raised its adjusted earnings-per-share forecasts for Erste Group for 2026–2028 by about 1%–2%. Net interest income was the main uplift, but forecasts for expenses and provisions were also raised.
Shares of Taiwanese apparel and footwear contract manufacturers have fallen by more than thirty percent on average this year, but JPMorgan believes low valuations will not bring a synchronized recovery: apparel makers have a clearer path to converting orders into profits, while footwear makers depend more on brand orders, product categories and capacity utilization.
TSMT’s optical module assembly business launched on schedule in the third quarter, while DRAM shipments rose about thirty percent quarter on quarter. JPMorgan expects high-value 1.6T products to partly offset the impact of component shortages, while lowering its earnings forecasts and price target.
Product sales rose 33% year on year in the third quarter of 2026, driving RemeGen to a second consecutive quarter of recurring profitability. J.P. Morgan is positive on the full-year product sales and break-even targets but has lowered its 2027 revenue forecast and its A- and H-share price targets.
Central bank and ETF purchases supported gold in the third quarter, while jewelry and bar and coin demand weakened at the same time; the US copper mining project pipeline has expanded, but most new supply will not arrive until after 2030.
Third-quarter DRAM price increases exceeded JPMorgan’s expectations, and HBM pricing negotiations also made progress; however, weakening PC and mobile phone demand and concerns about AI financing are weighing on memory stocks in the short term.
Domestic medical equipment tenders returned to year-on-year growth in the third quarter of 2026, while company revenues improved. JPMorgan believes changes in procurement rules and lower geopolitical sensitivity are also supporting sector performance.
Thailand plans to raise the excise tax on imported battery electric vehicles and range-extended electric vehicles that meet certain conditions to 35% from 2027. JPMorgan believes the industry impact from Thailand alone is manageable, but the accumulation of overseas trade barriers will restrain export growth, while localization could also weigh on short-term margins.
JPMorgan expects the Federal Reserve to raise rates again in December and maintains its call for a steeper U.S. Treasury curve. It remains overweight emerging-market currencies, but rate volatility and growth pressures are prompting the bank to narrow its selections. Meanwhile, economic growth in multiple countries is accompanied by falling oil demand.
GAC, SAIC, Changan and BAIC all reported third-quarter results below market expectations. JPMorgan believes their own brands cannot yet offset falling joint venture profits and expects a slow recovery in 2027.
Product sales rose 33% year over year in the third quarter of 2026, helping RemeGen achieve recurring profitability for a second consecutive quarter. J.P. Morgan is optimistic about new indications and overseas phase III trials, but has lowered its 2027 revenue forecast and price targets for the A and H shares.
A cleaning-product transition and earlier promotions weighed on third-quarter revenue, but charging, energy storage and audio supported recurring profit growth. J.P. Morgan lowered its full-year revenue forecast but still expects growth to improve in the fourth quarter.
Organic sales and profit both exceeded market expectations in the first quarter of fiscal 2027, with cost savings driving a recovery in profitability. Growth is expected to slow in the second half, however, and acquisitions and constraints on cash flow continue to influence the credit assessment.
Pfizer raised its 2026 guidance, and JPMorgan modestly increased its forecasts. However, the bank expects revenue and earnings per share to decline over the next two years, with data from most major pipeline programs due at the end of 2027 or later.
JPMorgan raised its revenue growth forecasts for Cloudflare over the next three years, seeing expansion among large customers and the developer business as potential growth drivers, while improved sales efficiency could support margins. However, the high valuation still places demanding expectations on growth and cash flow.
Logic-chip thermocompression bonding and AI server-driven SMT operations support growth, but HBM stacking layers have stalled. Management expects a more meaningful recovery in memory thermocompression bonding demand only by 2029.
Low costs and natural gas production supported third-quarter cash flow, and the base dividend was raised 7%; however, the company increased its full-year capital spending and gave fourth-quarter crude production guidance below expectations.
JPMorgan expects earnings at some chemical companies to rebound significantly in 2026, but the recovery is uneven; even among companies with low valuations, cash flow and debt levels differ substantially.